General characteristics and genetic nature
Primary enzymopathies represent a classic example of how alterations at the DNA level directly affect the biochemical profile of the organism. In the overwhelming majority of cases, these diseases are characterized by an autosomal recessive type of inheritance. This means that the pathology manifests only if the defective gene encoding the non-functioning enzyme was inherited from both parents. Once the blockade of enzymatic activity occurs, it inevitably triggers a pathological cascade based on the disruption of a specific metabolic pathway. The enzyme ceases to perform its function, the reaction halts, and a so-called "reaction block" arises.
Mechanism of the metabolic block
To better understand the pathogenesis of enzymopathies, it is helpful to examine an abstract scheme of a classical metabolic pathway consisting of a sequential chain of transformations: A → B → C → D → E → P.
In this normal physiological chain, each transformation is controlled by its own specific enzyme. Let us imagine that at the stage of converting substance C into substance D, a failure occurs — the enzyme (let us call it E3) turns out to be defective. A metabolic block arises.
The consequences of this block develop in two directions:
- Depletion of downstream metabolites: Substance C cannot be converted into D. Consequently, the body develops an acute deficiency of product D, as well as all subsequent substances in the chain — E and the final product P.
- Excess of precursors: Since the reaction is halted, the substrate C, which continues to arrive or be synthesized from A and B, begins to accumulate in an avalanche-like manner because it has nowhere to be utilized.
Scenario one: impaired formation of end products
The first and one of the most obvious scenarios for the development of pathology in enzymopathies is related to the body being deprived of vital compounds due to the enzymatic block. The shortage of certain final metabolic products leads to the loss of entire physiological functions.
A classic example of such a scenario is albinism (albinismus). In this pathology, an enzymatic defect makes it impossible to complete the biochemical pathway responsible for melanin synthesis. As a result, skin, hair, and iris cells completely fail to produce pigment, which shapes the patient's characteristic appearance and increases their vulnerability.
Scenario two: accumulation of precursor substrates
The second, equally severe scenario of disease development is associated with the "damming" effect upstream of the blocked section of the biochemical pathway. The accumulating precursor substrates are frequently not inert; at high concentrations, they begin to exert a pronounced toxic effect on various organs and systems of the body.
A striking clinical example of this mechanism is alkaptonuria (alkaptonuria). In this case, due to an enzyme defect, the breakdown chain of certain amino acids is interrupted. This leads to the massive accumulation of an intermediate metabolite — homogentisic acid. Being toxic in large amounts, homogentisic acid actively deposits in the tissues of cartilage and joints. Such abnormal deposition inevitably causes severe chronic inflammation and the gradual destruction of the joint apparatus, which becomes the main clinical manifestation of this enzymopathy.
Briefly: answers to topical questions
Which specific enzyme is defective in albinism?
In albinism, the defective enzyme is tyrosinase. Normally, it functions in melanocytes of the skin and eyes, where it catalyzes the initial stages of melanin synthesis — the conversion of tyrosine to DOPA. Because of this enzyme block, the formation of dark pigments is disrupted, pathogenetically leading to complete or partial lack of skin, hair, and iris pigmentation, as well as reduced visual acuity.
The metabolism of which specific amino acids is disrupted in alkaptonuria?
In alkaptonuria, the metabolism of the proteinogenic amino acids phenylalanine and tyrosine is disrupted. The block occurs at a specific stage of catabolism (breakdown) of these amino acids, specifically at the stage of homogentisic acid degradation. Due to this enzymatic defect, this intermediate metabolite is not broken down into end products, but rather accumulates in the body, becoming oxidized and depositing in cartilage tissue.
Which enzyme is non-functional in alkaptonuria?
In alkaptonuria, the enzyme homogentisate dioxygenase is non-functional. Synonymic names for this enzyme are also used in medical literature: homogentisate 1,2-dioxygenase, homogentisate oxidase, or homogentisic acid oxidase. The inactivity of the enzyme is most often associated with a gene mutation (missense mutation or nonsense mutation), which leads to the loss of its catalytic function and blocks the conversion of homogentisate to maleylacetoacetate.
What are some examples of enzymopathies other than alkaptonuria that proceed via the substrate accumulation scenario?
There are many hereditary enzymopathies that proceed via the scenario of intermediate substrate accumulation due to a metabolic pathway block. Such diseases include:
- Phenylketonuria — accumulation of phenylalanine and phenylpyruvate, which are toxic to the central nervous system, due to phenylalanine hydroxylase deficiency.
- Acute intermittent porphyria — accumulation of porphobilinogen due to PBG deaminase deficiency.
- Hereditary parenchymal lipidoses (thesaurismoses) — systemic accumulation of unmetabolized lipids (e.g., Gaucher disease or Niemann-Pick disease).
- Glycogen storage diseases (glycogenoses) — excessive accumulation of glycogen in tissues, for example, von Gierke disease due to glucose-6-phosphatase deficiency.
To easily remember the two scenarios of enzymopathy pathogenesis, imagine a broken assembly line. If a machine breaks down, the required parts are not produced (this is product deficiency — like the lack of pigment in albinism). At the same time, a huge pile of raw materials piles up in front of the broken machine, interfering with the work of the entire shop (this is the toxic accumulation of the precursor — like homogentisic acid in the joints in alkaptonuria).
Class and exam questions
What type of inheritance is most characteristic of primary enzymopathies?
In the overwhelming majority of cases, primary enzymopathies are inherited in an autosomal recessive manner.
What is the main mechanism of development (pathogenesis) of an enzymopathy?
The main mechanism is a defect in a specific enzyme, which leads to a block of the metabolic pathway. Because of this, the conversion of substrates into end products is disrupted.
Which substance accumulates in alkaptonuria and what does it lead to?
In alkaptonuria, an excessive accumulation of the intermediate metabolite, homogentisic acid, occurs. It deposits in the joints, causing inflammation and damage.
Why is skin color affected in albinism?
Due to a block in the metabolic reaction, the formation of the pathway's end products is disrupted; in this case, pigment is not produced in skin cells.
What else to study on this topic
- Detailed biochemical pathway of tyrosine conversion and causes of albinism development
- Mechanism of the toxic effect of homogentisic acid on cartilage tissue
- Autosomal recessive inheritance: genetic basis and probability of transmission to offspring
- Comparison of enzymatic blocks: impact on intermediate metabolites B, C, and D
- Diagnostic markers of enzymopathies associated with the accumulation of specific acids
Master the entire topic in the "Biochemistry" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Enzymopathies" and 3,616 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 115 video lessons on the subject
Other topics in the "Enzymology" section
Free video lessons: biochemistryShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.